CARLOS MANUEL
PANIZO SANTOS
![Foto de CARLOS MANUEL](/img/nophoto.png)
![Foto de Instituto de Investigación Sanitaria de Navarra](/img/noimage_org.png)
Instituto de Investigación Sanitaria de Navarra
Pamplona, EspañaInstituto de Investigación Sanitaria de Navarra-ko ikertzaileekin lankidetzan egindako argitalpenak (7)
2023
-
Venetoclax improves CD20 immunotherapy in a mouse model of MYC/BCL2 double-expressor diffuse large B-cell lymphoma
Journal for immunotherapy of cancer, Vol. 11, Núm. 2
2022
-
Phase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphoma
Leukemia and Lymphoma, Vol. 63, Núm. 4, pp. 821-833
2020
-
Ibrutinib does not have clinically relevant interactions with oral contraceptives or substrates of CYP3A and CYP2B6
Pharmacology Research and Perspectives, Vol. 8, Núm. 5
-
Maintenance therapy with ex vivo expanded lymphokine-activated killer cells and rituximab in patients with follicular lymphoma is safe and may delay disease progression
British Journal of Haematology, Vol. 189, Núm. 6, pp. 1064-1073
2019
-
The mechanism of action of the anti-CD38 monoclonal antibody isatuximab in multiple myeloma
Clinical Cancer Research, Vol. 25, Núm. 10, pp. 3176-3187
2018
-
Post-transplant lymphoproliferative disease after liver transplantation
Revista Espanola de Enfermedades Digestivas
2016
-
Follicular lymphoma: in vitro effects of combining lymphokine-activated killer (LAK) cell-induced cytotoxicity and rituximab- and obinutuzumab-dependent cellular cytotoxicity (ADCC) activity
Immunologic Research, Vol. 64, Núm. 2, pp. 548-557